Tuesday 25 February 2020

Global Anti-Viral Drugs Market Trend, Industry Overview, Competitive Analysis and Foreseen by 2023

Market Scenario:
The rising cases of viral disease is identified to boost the global anti-viral drugs market growth. The inadequacy of dietary nutrition in people, due to increase in consumption of high calorie and low fibrous food is creating favourable condition for virus to invade human body. Hence, the need for anti-viral drugs are surging as viral infections prevail. The growing incidences of HIV and other sexually-transmitted diseases are also boosting the sales number of anti-viral drugs, hence, anticipated to prompt the anti-viral drug market growth.
The increase in cases of drug resistance is propelling extensive research and developmental undertakings for launching more effective anti-viral drugs. Additionally, the stringency in drug approval stages are taking care of the quality of drugs in the pipeline. New product launches are gaining traction for revenue generation for the anti-viral drugs market. The application of anti-viral drugs in other diseases like, bird flu, and others is also likely to prompt the global anti-viral drug market growth.
The expiry of patents for certain blockbuster anti-viral drug are stimulating generic drug competition in the anti-viral drug market. This is deepening the competitive scenario of the global anti-viral drug market over the assessment period.
However, adverse effects of anti-viral drugs and high price of anti-viral drugs can hinder the anti-viral drugs market growth over the assessment period. 
Market Segmentation:
Global anti-viral drugs market has been segmented on the basis of on the basis of application, which comprises hepatitis, HIV/AIDS, herpes, influenza and others. On the basis of mechanism of action; market is segmented into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors and others.
Regional Analysis:
Depending on geographic region, anti-viral drugs market is segmented into four key regions: America, Europe, Asia Pacific, and Middle East & Africa. Globally, America is the largest market for anti-viral drugs with Europe tied for the second space. Asia Pacific region is expected to be fastest growing region in anti-viral drugs market. 
Key Players
MRFR have enlisted some of the prominent companies operating in the anti-viral drugs market. They are; Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., Gilead Sciences Inc., Cipla Inc. GlaxoSmithKline Plc, Novartis International AG, Abbott Laboratories, and  Astra Zeneca AB. 
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Age-Related Macular Degeneration Industry Growth, Trends and Forecast Till 2023 By MarketResearchFuture.com

Market scenario:
This MRFR study offers a vivid view of the global age-related macular degeneration AMD market. The study includes an in-depth analysis of macro and micro-economic factors likely to influence the market during the forecast period. It further summarizes the key market opportunities and trends.
The Global Age-Related Macular Degeneration Market size is expected to register a CAGR of 7.80% to reach USD 11,186.8 Million by 2023. Age-related macular degeneration (AMD) is a chronic irreversible medical condition that results in central vision loss because of damage to the central area of the retina (macula). This condition is majorly categorized as dry age-related macular degeneration and wet age-related macular degeneration.
Growing geriatric population and increasing prevalence of age-related macular degeneration, several branded drugs going off-patent are expected to enhance market growth. However, factors such as high cost associated with AMD, stringent FDA regulations may restrain the market growth during the forecast period.
Key Players
The prominent players in the global age-related macular degeneration market are Novartis AG, Pfizer Inc, F. Hoffmann-La Roche AG, Acucela Inc., Ophthotech Corporation, GlaxoSmithKline PLC, Bayer AG, Rxi Pharmaceuticals, Inc., Regeneron Pharmaceutical Inc., Alimera Sciences Inc., Santen Pharmaceuticals Co., ALLERGAN, and Bausch & Lomb Incorporate.
Market Dynamics
The global age-related macular degeneration market has been primarily driven by growing geriatric population and increasing prevalence of age-related macular degeneration, several branded drugs going off patent. For instance, according to the 2017 statistics suggested by the United Nations, it was estimated that 962 million people aged 60 or above comprise 13% of the global population. Factors such as high cost associated with AMD, stringent FDA regulations may restrain the market growth during the forecast period.
Segmentation
The global age-related macular degeneration market has been segmented into type, stages, age group, treatment, and route of administration. Based on type, the market has been classified as wet age-related macular degeneration (wet AMD) and dry age-related macular degeneration (dry AMD). Dry age-related macular degeneration (dry AMD) held a market share of 2,092.6 USD million in 2017. Based on stages the market has been divided into intermediate-stage age-related macular degeneration, early-stage age-related macular degeneration, late-stage age-related macular degeneration. On the basis of age group, the market has been bifurcated into above 75 years, above 60 years, and 40 years. Based on treatment, the market has been divided into treatment and Diagnosis. Based on the route of administration, the market has been classified as an intravitreal route of administration and intravenous route of administration. Based on the end user, the market has been segmented into hospital & clinics, diagnostic centers, and academic research institutes.
Regional Analysis
The global age-related macular degeneration market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas dominate the global age-related macular degeneration market is owing to the rising ophthalmological disorders and increasing aging population. Nearly 7.3 million people are at significant risk of vision loss due to AMD.
Europe holds the second largest market share due to increasing older population and rising patient population. Additionally, improving government initiatives and increasing healthcare frame along with growing demand for technologically innovative treatment is driving the growth of age-related macular degeneration market in Europe
Asia-Pacific is estimated to be the fastest-growing region in the global age-related macular degeneration as it is developing at a very rapid pace and has shown the emergence of many players. Moreover, rising prevalence of eye disorders, increasing healthcare spending, and multinational companies moving towards the developing nations and setting operational set-ups are likely to drive the growth of the market. Japan held a market share of 23.2% in 2017.
The Middle East & Africa are expected to witness restricted growth due to limited access and healthcare affordability among the population. In the Middle East, the growth of the market is driven by increasing healthcare infrastructure and healthcare expenditure.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

International Genetic Testing Market and Prominence 2023 on Consumer Needs, Revenue, Pricing strategy and Growth Rate

Market Synopsis of Global Genetic testing Market:
Genetic Testing Market size is expected to grow at CAGR of 11.50% to reach USD 22834.19 million till 2024, revealed by Market Research Future (MRFR) with Global Genetic Testing Market Analysis by by Type, Method, by Application, and Regions - Americas, Europe, Asia-Pacific and Middle East & Africa and Forecast till 2024
Key Players
The prominent players in the global genetic testing market are Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), Illumina Inc. (US), Myriad Genetics, Inc. (US), PerkinElmer Inc. (US), QIAGEN N. V.  (Germany), Quest Diagnostics Incorporated (US), Eurofins Scientific (US), F. Hoffmann-La Roche Ltd (Switzerland), Blueprint Genetics (Finland), BGI Genomics (China), and Thermo Fisher Scientific Inc. (US).
Market Insights:
Genetic testing is also known as DNA testing. Genetic tests involve a set of lab tests for the study of the genetic makeup of patients and identify any gene mutations and alterations in the healthy structure of DNA leading to the development of genetic disorders.
Some of the protuberant drivers supporting the growth of the global genetic testing market are identified as raising awareness about the benefits of genetic testing and the rising prevalence of genetic disorders.
Additionally, the role of genetic tests in forensic investigations and change in the trend of the genetic testing industry from service-driven to product-driven industry are expected to drive the global genetic testing market in the coming years.
Genetic testing offers a lot of benefits such as the chance for taking preventive measures to avoid potential diseases and lead a healthy life, knowledge about genetic alterations in the fetus that may lead to abnormal growth, and aids forensic investigations, among others. Due to the great benefits provided by these tests, people are getting more aware of them. This phenomenon intrigues people to go for tests to understand their genetic structure and possible disorders they may have to go through. The growing awareness has gathered a lot of audience for the genetic testing market and has also positively impacted the growth of this market.
Moreover, there has been tremendous growth in the prevalence of genetic disorders which may be due to various reasons such as geographical and environmental changes, change in food habits, pollution, and exposure to harmful radiations or chemicals. Genetic tests are also used to analyze family relations such as father, mother, half-brother, half-sister, and others. Forensic science and genetic testing have aided law and order to a great extent. With an increasing number of companies entering into this segment, the overall market for genetic tests has increased and expected to grow fast in the near future.
Some of the key strategies followed by the players operating in the global genetic testing market were innovation, product development, acquisition, and expansion.
  • In April 2017, Myriad Genetics, Inc. signed an agreement with Clovis Oncology for the use of its FDA-Approved BRACAnalysis CDx Test to identify patients with germline BRCA Mutations for the Rubraca (rucaparib) treatment.
  • In January 2017, Bio-Rad Laboratories, Inc. announced the launch of the Single Cell Sequencing Solution in collaboration with Illumina Inc.
  • In August 2016, Abbott Laboratories launched Alinity, a family of next-generation system.
Segmentation                                                                                                                                        
Global genetic testing Market, by type, segmented into prescribed genetic testing and direct to consumer genetic testing. Prescribed genetic testing is the leading segment, which is growing at the highest CAGR to reach USD 21653.91 million by the end of 2024. Its large market share is majorly attributed to the widespread availability and service providers of various genetic tests and less availability of direct to consumer tests in all parts of the world.
Based on method, the genetic testing market is segmented into molecular genetic tests/ DNA tests, chromosomal genetic tests, and biochemical genetic tests. The molecular genetic test/DNA tests account for major share with 11.78% CAGR during the forecast period. Molecular testing helps to determine the sequence in DNA or RNA related to a particular disease.
The genetic testing market, by application, is segmented into reproductive health, cancer screening, ancestry, predictive and pre-symptomatic testing, and others. The reproductive health segment accounted for the largest market share of 33.61% in 2018.
Regional Analysis         
The Americas accounted for the largest market share of the global genetic testing market, by region in 2018. This large share is majorly due to high awareness about genetic testing, high disposable income of the population, and implementation of newborn screening in the majority of the hospitals in the region. In 2015, approximately 12 million Americans suffered from genetic diseases which are approximately 1 in 20 people.
Europe accounted for the second largest market share. Technological advances, well-developed health care sector, and governmental support for the research and development of different tests and devices have provided fuel for the growth of the market. Germany commands the largest market share in the Europe genetic testing market.
Asia-Pacific is the fastest growing region for genetic testing. The presence of a huge patient population, rapid development in technology, and the presence of huge opportunities for the development of the market drive the growth of the Asia-Pacific genetic testing market. The Middle East & Africa accounted for the 8.8% market share in 2018.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

World VOCAL CORD PARALYSIS Market Estimation of Top Key Players Shares, Revenue, Analysis and Forecasts Till 2023

Global Vocal Cord Paralysis Market: Information by Type (Unilateral and Bilateral), Treatment (Voice Therapy and Surgery) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2023
Market Dynamics
Vocal Cord Paralysis Market is driven by rising prevalence of causing factors of vocal cord paralysis and technological advancements. For instance, according to the American Cancer Society, the estimated number of new cancer cases involving larynx was 13,360 in the US for the year 2017. Moreover, increasing healthcare expenditure has fueled the growth of the market. On the other hand, the high cost of treatment is anticipated to hamper the market growth.
Market Scenario
The Global Vocal Cord Paralysis Treatment Market is expected to register a CAGR of 3.8%and is anticipated to reach USD 2,920.2 Million by 2023. Vocal cord paralysis is caused by the disruption of nerve impulses to the muscles of the larynx or voice box. It may be caused by injury to the head, neck, or chest; lung or thyroid cancer; tumors of the neck or chest; or infection. The nerves controlling the vocal cords are long and can be vulnerable to injury in parts of the body, not usually associated with the vocal cords.
The increasing prevalence of causing factors of vocal cord paralysis, technological advancements, and growing healthcare expenditure are the major drivers propelling market growth. However, the high cost associated with the treatment is expected to constrain the growth of the market.
Competitive Landscape
Key players in the vocal cord paralysis market include Cytophil, Inc. (U.S.), Teleflex Incorporated (U.S.), Medtronic Plc (U.S.), Olympus Corporation (Japan), Stryker Corporation (U.S.), FUJIFILM Holdings Corporation (Japan), LifeCell Corporation (U.S.), Therapy Solutions Inc. (U.S.), KARL STORZ GmbH & Co. KG (Germany), and Smiths Group Plc (U.K.).

The report offers a comprehensive analysis on the profiles on these market players and assesses their current standing in the market. Company history coupled with annual turnover, profit margins, segmental share, SWOT analysis, growth strategies, expansion techniques, and latest R&D initiatives are discussed in minute detail.
Segmentation
By type, the market is divided into unilateral and bilateral. Treatment options in the vocal cord paralysis market voice therapy and surgery. The surgery treatment segment is further divided into structural implants, tracheotomy, bulk injection (phonosurgery), and vocal cord repositioning. The segments covered in the vocal cord paralysis market report are analyzed with respect to four regions namely – Americas, Middle East & Africa (MEA), Asia Pacific (APAC), and Europe. The report discusses in detail the various players residing in these regions and their respective strategies to climb up the market standings.
Regional Analysis
By region, the global vocal cord paralysis market has been segmented into the Americas, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA).
The Americas accounted for the largest share of 35.4% share of the global market in 2017 and is due to reach USD 1,007.5 Mn in 2023 at a CAGR of 3.4% by the end of the forecast period. Robust healthcare sector, technological superiority, and rising expenditure ion healthcare sector drive the market in the Americas. In addition, the region is highly aware of the medical condition which is acts a plus for the growth of the market.
Europe is a prominent market for vocal cord paralysis and is likely to scale valuation of USD 958.1 Mn at a CAGR of 4% by the end of the forecast period. Similar factors spur the Europe market as the Americas. Also, favorable reimbursement policies and high government support create a conducive environment for the growth of the Europe vocal cord paralysis market.
APAC vocal cord paralysis market is likely to exhibit rapid growth over the forecast period and emerge as the fastest growing market over the forecast period. The increasing prevalence of laryngeal cancer, availability of affordable treatment options and high expenditure on healthcare drive the market in APAC. The APAC market is expected to capture a CAGR of 4.11% over the forecast period.
The MEA market for vocal cord is expected to hold the least share of the market and expand at a CAGR of 3.90% over the forecast period.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

ICP-OES SPECTROMETER Market SWOT Analysis, Major Key Players Revenue, Analysis and Forecasts to 2023

ICP-OES Spectrometer Market Highlights:
ICP-OES Spectrometer is an analytical instrument that is used for the detection of chemical elements. It uses the technique of inductively coupled plasma optical emission spectroscopy (ICP-OES) for carrying out its analysis procedure. Certain factors that propel the growth of the ICP-OES spectrometer market insights include increasing R&D expenditure for the development of better analytical systems and growing technological advancements.
However, the high cost of instruments and requirement of large capital investment for setting up instrument manufacturing plants is hindering the growth of the global ICP-OES spectrometer market in the forecast period.
The Global ICP-OES Spectrometer Market size is expected to register a CAGR of 7.2% during the forecast period of 2019 to 2025 with a market value of USD 521.4 million in 2018.
Currently, the global ICP-OES spectrometer market is dominated by several players. The major players in this market are involved in strategic acquisitions and product launches to expand their product portfolios. For instance, in March 2016, GBC Scientific Equipment launched the OptiMass 9600, which uses the ICP-OES spectrometer technology.
Key Players:
Some of the key players in the global ICP-OES spectrometer market are PerkinElmer Inc. (US), Shimadzu Corporation (Japan), GBC Scientific Equipment (Australia), Thermo Fisher Scientific (US), Agilent Technologies, Inc. (US), SPECTRO Analytical Instruments GmbH (Germany), Teledyne Leeman Labs (US), Analytik Jena AG (Germany), Horiba (Japan), Skyray Instrument Inc. (US), Beijing Huake Tiancheng Technology Co., Ltd (China), FPI (China), Hitachi High-Technologies Corporation (Japan), Merck KGaA (Germany), and others.
Segmentation:
The global ICP-OES spectrometer market has been segmented based on spectrometer type, application, and end user.
The market, based on spectrometer type, has been bifurcated into sequential and simultaneous. The sequential spectrometer market is expected to hold a major share in the market owing to its wider availability in the market. The simultaneous spectrometer segment is anticipated to be the fastest growing due to its rising adoption rate.
The market, by application, has been divided into nanotechnology, drug discovery, environmental testing, food & agriculture, and others. The drug discovery segment is expected to hold a major share owing to a large number of applications of ICP-OES spectrometer in this field. The environmental testing segment is expected to be the fastest growing due to an increasing number of research activities for using ICP-OES spectrometer for environmental testing purpose.
The market, by end user, has been classified as pharmaceutical & biotechnology companies, research & academic institutes, and others. Pharmaceutical & biotechnology companies are anticipated to hold a major share in the market. This is due to the increasing number of applications of ICP-OES spectrometer in the pharmaceutical industry. The research & academic institutes segment is expected to become the fastest growing market due to the increasing research activities.
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The ICP-OES spectrometer market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European ICP-OES spectrometer market has been sub-divided Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe. The ICP-OES spectrometer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The ICP-OES spectrometer market in the Middle East & Africa has been divided into the Middle East and Africa.
Regional Analysis:
The market in the Americas is expected to dominate the global ICP-OES spectrometer market due to the growing expenditure on R&D to develop new technologies and the high adoption of new technology in the region. Moreover, the presence of major companies such as PerkinElmer Inc., Agilent Technologies, Inc., Thermo Fisher Scientific, etc. in North America is also expected to fuel the market growth in the region.
The market in Europe showed a substantial amount of growth. The market growth in this region can be attributed to the presence of a well-established healthcare system and increasing adoption of ICP-OES spectrometer for research purposes.
The market in Asia-Pacific is projected to have the fastest growth rate during the forecast period owing to the rapid growth of the pharmaceutical industry in countries such as China, India, and Japan.
The market in the Middle East & Africa is anticipated to account for the least share of the global market due to low disposable income in the region. Moreover, the presence of major companies in the Middle East and African market is also limited, which is projected to curb the growth of the market in the future.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future      
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028         
Maharashtra, India
Phone: +1 646 845 9312

LABORATORY INFORMATICS Market SWOT Analysis, Major Key Players Revenue, Analysis and Forecasts to 2023

Laboratory Informatics Market Highlights:
The global laboratory informatics market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 2422 million in 2018 and is projected to register a CAGR of 7.2% over the forecast period.
The increasing participation of key players is one of the key factors driving the market, says MRFR’s Global Laboratory Informatics market. In 2018, Abbott Laboratories announced the launch of the STARLIMS Quality Manufacturing Solution QM 11.1 to support laboratory productivity and efficiency across diverse sectors of the global manufacturing industry.
Various other factors such as the increase in adoption of cloud-based platforms by CROs, increasing preference towards personalized medicine, untapped emerging markets, rise in regulatory approvals, and rising R&D in the field of medicine are also expected to propel the growth of the market.
However, high maintenance and service costs can hamper market growth over the forecast period.
Key Players:
Some of the key players in the global laboratory informatics market are Agilent Technologies, Inc., Abbott Laboratories, Accelerated Technology Laboratories, Cerner Corporation, Dassault Systèmes, IDBS, KineMatik, Lablynx, Inc., Labvantage Solutions, Inc., Autoscribe Limited, Labware, Labworks LLC, McKesson Corporation, Thermo Fisher Scientific Inc., Perkinelmer Inc., Waters, and others.
Segmentation:
The global laboratory informatics market is segmented based on product, component, deployment model, end user, and region.
The global market for laboratory informatics, by product, is segmented into Laboratory Information Management Systems (LIMS), Chromatography Data Systems (CDS), Electronic Lab Notebooks (ELN), Electronic Data Capture (EDC) & Clinical Data Management Systems (CDMS), Laboratory Execution Systems (LES), Enterprise Content Management (ECM), and Scientific Data Management Systems (SDMS). The Laboratory Information Management Systems (LIMS) segment is further classified as broad-based LIMS and industry-specific LIMS.
Based on component, the market is segmented into software and services.
Based on the deployment model, the market is segmented into on-premise models, cloud-based models, and remotely hosted models.
Based on end user, the market is segmented into life sciences companies, CROs, environmental testing laboratories, and others.
In the current scope of the study, the segments mentioned above are covered into the four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and African region.
The laboratory informatics market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European laboratory informatics market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The laboratory informatics market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The laboratory informatics market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Analysis:
The Americas dominated the global market for laboratory clinical informatics owing to the escalating healthcare cost coupled with the rising pressure to bend the cost curve resulted in increased regional adoption of laboratory information management systems. According to the Organization for Economic Co-Operation and Development, in 2018, Americans spent USD 3.65 trillion on healthcare. It is also stated that the level of spending is by far the highest in the developed world.
In 2018, it was estimated that Europe stood second in the global laboratory informatics market. Technological advancements, along with the availability of funding opportunities in research and innovation, will support the growth of healthcare laboratory informatics. Germany commanded the largest share in the European market for medical laboratory informatics due to growing automation of laboratory systems.
Asia-Pacific (APAC) is expected to represent the phenomenal growth in medical informatics throughout the forecast period due to rising participation of market players and increasing healthcare funding. In 2018, Sysmex Corporation, Japan-based company, launched a new network solution Caresphere. The solution is designed to provide new value through the intelligent use of information by people involved in testing and healthcare.
On the other hand, the Middle East and Africa held the least share in the global Laboratory Informatics market due to the low economic development, especially within the African region.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future      
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028         
Maharashtra, India
Phone: +1 646 845 9312

Global CBD Market Trend, Industry Overview, Competitive Analysis and Foreseen by 2023

CBD Market Overview
The Global Cannabidiol Market also known as CBD Market is expected to register a CAGR of 125.58% to reach USD 22,07,162.54 Million by 2026.
Cannabidiol (CBD) is a safe, non-addictive substance found in the cannabis plant. CBD is the second-most abundant cannabinoid found in cannabis after tetrahydrocannabinol (THC). CBD has significant therapeutic benefits such as anti-inflammatory, analgesic, anti-anxiety, and seizure-suppressant properties. According to a survey by the National Center for Biotechnology Information (NCBI) conducted between 2017 and 2018, about 62% of the population used CBD to treat a medical condition.
The growing research & development and financial support by various private and government organizations for cannabinoid research, rising occurrence of chronic diseases and related complications, and legalization of CBD in various regions are expected to have a positive impact on the global cannabidiol (CBD) market. However, adverse effects associated with cannabis and stringent government policies are anticipated to restrain the growth of the global CBD market.
CBD Market Dynamics
Growing research and development activities and financial support by various private and government organizations for cannabinoid research- There are many private and government organizations supporting the research and development for cannabinoids for medical purposes. Cannabis has numerous medicinal properties by which it can cure various diseases. According to the National Institute of Drug Abuse, May 2018 publication, in 2017, the National Institute of Health (NIH) supported 330 projects and spent USD 140 million on cannabinoid research and development. During this investment, USD 36 million was spent on 70 projects to examine the therapeutic properties of cannabis, and USD 15 million was spent on 26 projects centered on cannabinoid (CBD). Even in 2016, NIH spent USD 21 million studying therapeutic properties of cannabinoids. Singapore, known for the world's most stringent drug laws, is also funding research projects on medical treatments containing synthetically derived compounds of the cannabis plant. In 2017, the government-run National Research Foundation launched a program to research the therapeutic potential of cannabinoids.
CBD Market Regional Analysis
The Americas dominate the global CBD market, owing to the increasing consumption of cannabis-based products. According to the World Health Organization (WHO), the consumption of marijuana has an annual prevalence rate of nearly 2.5% of the global population, i.e., approximately 147 million individuals. It is also reported that approximately 22.2 million Americans of 12 years of age and older use cannabis and related products for various reasons.
Europe holds the second largest market share due to the rising awareness about clinical applications of cannabis. CBD is legal and can be openly marketed in certain European countries, for instance, the Ministry of Agriculture, Food and Forestry, and the Bulgarian Food Safety Agency issued the ‘free certificate of sale’ for the CBD products. Thus, such approvals and consideration by the regulatory agencies in Europe are driving the CBD market growth in the region. In spite of the approvals and considerations, there are positive restrictions associated with the use of the products. For instance, in 2013, medical cannabis was legalized in the Czech Republic, but it was limited to 180 grams of dry matter per month. In Europe, marijuana and cannabis laws differ from country to country. Previously, Germany was importing medical cannabis from other countries, but in 2017, Germany passed a law to expand access to medical cannabis and to allow domestic production. Increasing participation of various companies such as Medical Marijuana Inc., as a scope of development, announced the formation of Canipa Holdings in Romania, European Union. The effect of such initiatives by the companies is facilitating the growth of the CBD market in the European region.
The Asia-Pacific region is classified into CBD Market China, CBD Market India, CBD Market Japan, and Rest of Asia-Pacific. It holds the third largest position in the CBD market. Recently, China has legalized the cultivation of CBD (Hemp) and extraction for the derived product. The products are exported and not sold in China. Yunnan provincial government and Public Security Bureau approved the first industrial hemp plant extraction factory in China. It is the largest country in terms of area, population, businesses, and others. The entry of Chinese companies in the CBD market has created a great potential for expansion and growth. In Asia-Pacific, cannabis-based products are completely unacceptable. But due to the increasing cases of epilepsy, cannabis-based products are prescribed by some physicians. For instance, a recent Australian nationwide survey of 976 people with epilepsy indicated that 13% of the parents were using illicit cannabis extracts to manage their child’s seizures. Australia mainly focuses on the medical use of cannabis products. Australian regulatory agencies are operating on providing a guideline for the use of the CBD products. This is expected to help in the growth of the CBD market in Australia.
The Middle East and Africa is expected to witness a restricted growth due to stringent government policies, adverse effects associated with cannabis, and the illegal use of marijuana. In the Middle East, few of the Arab countries are imposing trick laws over the use and handling of cannabis-related products. Thus, the CBD market in these regions has limited scope for growth during the forecast period.
Segmentation
On the basis of form, the global cannabidiol market is segmented into solid and liquid.
In the solid form of CBD, the report covers CBD crystals, CBD wax, capsule/softgel, hash, and others. The liquid form of CBD includes CBD oil, tincture, cream, e-liquid, and others.
CBD crystals are a pure form of CBD isolates. CBD crystals are produced by heating CBD rich extract and then continuous cooling and separating it. CBD crystals are generally used to manufacture CBD infused edibles and creams. CBD wax is solidified or crystalized full spectrum form of CBD. CBD wax is a highly concentrated form of CBD and especially used for pain relief. CBD capsules are similar in comparison to capsules as they are surrounded by an outer shell, usually gelatin. CBD soft gelatin capsule is a translucent golden shade standard capsule that is filled with hemp oil and sometimes olive oil as filler.
CBD oil is one of the most popular and widely available forms of CBD. It is specifically used for medical purposes as it provides fast and effective results. There are a wide variety of flavors of full spectrum CBD oils available in the market. CBD tinctures are made from high strains of hemp, with 60-70% of alcohol. CBD tinctures are primarily used to relieve anxiety and ease the pain. CBD infused e-liquid are used as a fluid in electronic cigarettes and vaporizers.
CBD Market Key Players
The prominent players in the global CBD market are Aphria Inc., Folium Biosciences, Freedom Leaf, Inc, Green Roads of Florida, LLC, CBD Health Solutions, LLC, ENDOCA, Isodiol International Inc, CV Sciences, Inc, Medical Marijuana, Inc., Canopy Growth Corporation, Elixinol Global Limited.
The players operating in the global CBD market are focusing on product launches, along with expanding their global footprints by entering untapped markets.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312